Boston Scientific said that its revenue grew 2% during the second quarter, excluding foreign exchange effects and the impact from divested businesses. The company said sales of its neuromodulation devices rose 21% during that period and added that while sales of its stents and defibrillators decreased, the rate of decline was slower in the second quarter compared with that of the first quarter.

Full Story:

Related Summaries